中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
22期
2184-2186
,共3页
万古霉素%新生儿败血症%免疫功能%不良反应%疗效
萬古黴素%新生兒敗血癥%免疫功能%不良反應%療效
만고매소%신생인패혈증%면역공능%불량반응%료효
vancomycin%neonatal sepsis%immune function%adverse drug reaction%efficacy
目的 评价万古霉素对新生儿败血症患儿的临床预后及免疫功能的影响.方法 入选53例新生儿败血症患儿为试验组,选取同期在我院产科出生的53例正常新生儿作为对照组. 新生儿败血症患儿用头孢硫脒加哌拉西林/舒巴坦进行治疗,明确耐甲氧西林金黄色葡萄球菌败血症患儿改为静脉滴注万古霉素15 mg·kg-1 ,每天1次,治疗7~10 d,观察新生儿败血症患儿在治疗前后的临床疗效,2组新生儿治疗前后的可溶性白细胞介素-2受体( sIL-2R)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、膜白细胞介素-2受体(mIL-2R)变化和不良反应. 结果 治疗后,试验组和对照组的免疫功能指标比较,差异无统计学意义( P>0.05). 万古霉素治疗后,新生儿败血症患儿有效率为85.72%,显著高于治疗前的28.57%( P<0.05 ). 使用万古霉素治疗后患儿出现的皮疹、恶心、呕吐、腹泻及静脉炎等不良反应和未使用万古霉素比较,差异无统计学意义( P>0.05 ).结论 万古霉素可有效改善新生儿败血症患儿免疫功能,不良反应轻,有利于患儿的临床预后.
目的 評價萬古黴素對新生兒敗血癥患兒的臨床預後及免疫功能的影響.方法 入選53例新生兒敗血癥患兒為試驗組,選取同期在我院產科齣生的53例正常新生兒作為對照組. 新生兒敗血癥患兒用頭孢硫脒加哌拉西林/舒巴坦進行治療,明確耐甲氧西林金黃色葡萄毬菌敗血癥患兒改為靜脈滴註萬古黴素15 mg·kg-1 ,每天1次,治療7~10 d,觀察新生兒敗血癥患兒在治療前後的臨床療效,2組新生兒治療前後的可溶性白細胞介素-2受體( sIL-2R)、免疫毬蛋白G(IgG)、免疫毬蛋白M(IgM)、膜白細胞介素-2受體(mIL-2R)變化和不良反應. 結果 治療後,試驗組和對照組的免疫功能指標比較,差異無統計學意義( P>0.05). 萬古黴素治療後,新生兒敗血癥患兒有效率為85.72%,顯著高于治療前的28.57%( P<0.05 ). 使用萬古黴素治療後患兒齣現的皮疹、噁心、嘔吐、腹瀉及靜脈炎等不良反應和未使用萬古黴素比較,差異無統計學意義( P>0.05 ).結論 萬古黴素可有效改善新生兒敗血癥患兒免疫功能,不良反應輕,有利于患兒的臨床預後.
목적 평개만고매소대신생인패혈증환인적림상예후급면역공능적영향.방법 입선53례신생인패혈증환인위시험조,선취동기재아원산과출생적53례정상신생인작위대조조. 신생인패혈증환인용두포류미가고랍서림/서파탄진행치료,명학내갑양서림금황색포도구균패혈증환인개위정맥적주만고매소15 mg·kg-1 ,매천1차,치료7~10 d,관찰신생인패혈증환인재치료전후적림상료효,2조신생인치료전후적가용성백세포개소-2수체( sIL-2R)、면역구단백G(IgG)、면역구단백M(IgM)、막백세포개소-2수체(mIL-2R)변화화불량반응. 결과 치료후,시험조화대조조적면역공능지표비교,차이무통계학의의( P>0.05). 만고매소치료후,신생인패혈증환인유효솔위85.72%,현저고우치료전적28.57%( P<0.05 ). 사용만고매소치료후환인출현적피진、악심、구토、복사급정맥염등불량반응화미사용만고매소비교,차이무통계학의의( P>0.05 ).결론 만고매소가유효개선신생인패혈증환인면역공능,불량반응경,유리우환인적림상예후.
Objective To study the influence of vancomycin on clinical effects and immune function of neonatal sepsis.Methods A total of 53 neonatal sepsis treated in our hospital were selected as the test group, and 53 health normal newborns in the same period in our hospital were selected as the control group.All neonatal sepsis were treated with cefa-thiamidine combined with piperacillin sulbactam, and neonatal sepsis that infected by methicillin-resistant Staphylococcus aureus were treated with vancomycin 15 mg·kg-1 , 1 times a day, and 7 -10 d was a course.After treatment, clinical efficacy and adverse reactions of chil-dren in test group were observed. Soluble interleukin -2 receptor ( sIL-2R) , immunoglobulin G ( IgG ) , immunoglobulin M ( IgM ) , membrance interleukin -2 receptor ( mIL -2 R ) of children changes before and after treatment were compared in two groups.Results After treatment, immune function indicators of neonatal sepsis and normal newborns were compared which showed no significant difference (P>0.05).After vancomycin treatment, total effective rate of neonatal sepsis was 85.72%, which was higher than that before treated with vancomycin (28.57%, P<0.05); and immune function parameters of newborns with Staphylococcus aureus septicemia was improved obviously, which had no significant difference compared with that of normal newborns ( P>0.05).The incidence of adverse reactions such as rash, nausea, vomiting, diarrhea and phlebitis before and after treatmemt with vancomycin had no significant difference ( P >0.05 ) . Conclusion Vancomycin can effectively improve the immune function in children with neonatal sepsis and reduce ad-verse drug reactions, which can be also conducive to clinical outcomes of children.
